Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16673698 | 0.76 | PDE10A (0.41) | DAOPKMKDM4ERAB9ANPC1 | |
| SCHEMBL14486302 | 0.75 | DAO (0.68) | DAOKDM4ELMNA | |
| SCHEMBL14554731 | 0.75 | PKM (0.48) | PKMKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14488513 | 0.75 | KDM4E (0.46) | PKMKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14488071 | 0.74 | DAO (1.00) | DAO | |
| SCHEMBL14486273 | 0.73 | DAO (1.00) | DAO | |
| SCHEMBL6035011 | 0.73 | PKM (0.56) | PKMKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10666500 | 0.72 | NPC1 (1.00) | PKMKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14486127 | 0.70 | DAO (0.64) | DAOMEN1KMT2A | |
| SCHEMBL14486325 | 0.70 | DAO (1.00) | DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | claimed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | claimed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | claimed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | claimed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | claimed |
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TPMT, DHFR, DPYD | DAO 934/4885PKM 238/4885KDM4E 790/4885 |
| US-10085986-B2 | Pyrimidinone compounds and their use | TPMT, DHFR, DPYD | DAO 934/4885PKM 238/4885KDM4E 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.